Prior Covid offers less protection vs Omicron; mRNA booster shot efficacy declines within months
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Wednesday
February 08, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
WEDNESDAY, FEBRUARY 08, 2023
Prior Covid offers less protection vs Omicron; mRNA booster shot efficacy declines within months

Coronavirus chronicle

Reuters
15 February, 2022, 02:05 pm
Last modified: 15 February, 2022, 05:03 pm

Related News

  • Omicron subvariant XBB.1.5 may be dominant in Europe soon: Health agency
  • 'Covid cases still low but no alternative to caution'
  • DGHS urges to wear masks, take booster dose amid fresh Covid outbreak in China, India
  • Can mRNA vaccines cure cancer?
  • China's Xi told EU less lethal Omicron opens way for fewer Covid restrictions

Prior Covid offers less protection vs Omicron; mRNA booster shot efficacy declines within months

The immune response to Covid-19 helps protect against reinfection, but that protection is weaker against Omicron than it was against earlier variants of the coronavirus, according to new data

Reuters
15 February, 2022, 02:05 pm
Last modified: 15 February, 2022, 05:03 pm
Test tube labelled "Covid-19 Omicron variant test positive" is seen in this illustration picture taken January 15, 2022. Photo :Reuters
Test tube labelled "Covid-19 Omicron variant test positive" is seen in this illustration picture taken January 15, 2022. Photo :Reuters

The following is a summary of some recent studies on Covid-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

Previous Covid-19 less protective against Omicron variant

The immune response to Covid-19 helps protect against reinfection, but that protection is weaker against Omicron than it was against earlier variants of the coronavirus, according to new data.

A previous SARS-CoV-2 infection protects against Omicron reinfection only 56% of the time, researchers found in a review of national data in Qatar. Having had Covid was 90.2% effective against reinfection with the Alpha variant, 85.7% effective against a Beta variant reinfection, and 92% effective against Delta reinfection, researchers reported on Wednesday in The New England Journal of Medicine.

As was the case with reinfection due to earlier variants, however, "the protection of previous infection against hospitalization or death caused by reinfection (with Omicron) appeared to be robust," they said. In cases of reinfection with Omicron, for example, the immune response to previous infection was 87.8% effective at preventing the second infection from progressing to severe or critical illness or death.

mRNA vaccine booster protection declines within months

Protection provided by booster shots of the mRNA vaccines from Moderna Inc or Pfizer Inc and partner BioNTech SE starts waning quickly, according to data published in Friday's Morbidity and Mortality Weekly Report  from the US Centers for Disease Control and Prevention (CDC).

Researchers reported that within two months after the second dose of an mRNA vaccine during the surge in infections caused by the Delta variant of the virus, vaccine efficacy was 94% against hospitalization and 92% against emergency department or urgent care (ED/UC) visits. Efficacy waned thereafter, but climbed to 96% and 97%, respectively, at two months after a booster shot. Four months later, however, that protection had declined to 76% and 89%. Once Omicron became predominant, vaccine efficacy was 71% against hospitalization and 69% against ED/UC visits within two months after the second dose, 91% and 87% at two months after a booster, and 78% and 66% four months later. The estimates are drawn from analyses of 241,204 Covid-related ED/UC visits and 93,408 hospitalizations between August and January.

"Our findings suggest that additional doses (of vaccines) may be necessary," Brian Dixon of the Regenstrief Institute and Indiana University said in a statement. "We also found that people who are Hispanic or Black are half as likely to have a third vaccine dose than people who are white, making (them) more vulnerable to severe Covid."

Top News / World+Biz

omicron / mRNA / booster

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • RMG turns to India from China to get cheaper man-made yarn
    RMG turns to India from China to get cheaper man-made yarn
  • Country's revenue earnings were Tk40,000cr more in last fiscal: Finance Minister
    Country's revenue earnings were Tk40,000cr more in last fiscal: Finance Minister
  • The world's richest person is trying to head off a succession battle
    The world's richest person is trying to head off a succession battle

MOST VIEWED

  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong will give away half a million plane tickets. Here’s who can get them first
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs

Related News

  • Omicron subvariant XBB.1.5 may be dominant in Europe soon: Health agency
  • 'Covid cases still low but no alternative to caution'
  • DGHS urges to wear masks, take booster dose amid fresh Covid outbreak in China, India
  • Can mRNA vaccines cure cancer?
  • China's Xi told EU less lethal Omicron opens way for fewer Covid restrictions

Features

Photo: Reuters

A tragedy that will also shake up the region's geopolitics

12h | Panorama
Nimah designed by Compass Architects- Wooden tiles. Photo: Junaid Hasan Pranto

Trendy flooring designs to upgrade any space

23h | Habitat
Benefits of having high ceilings in your new home

Benefits of having high ceilings in your new home

23h | Habitat
Each Reverse Osmosi plant can produce approximately 8,000 litres of drinking water a day for around 250 families. Photo: Sadiqur Rahman

A drop in the ocean of persistent water crisis

1d | Panorama

More Videos from TBS

30% companies see double-digit growth even in hard times

30% companies see double-digit growth even in hard times

15h | TBS Insight
Challenging time waiting for RMG

Challenging time waiting for RMG

22h | TBS Round Table
"Full Moon Meditation" organized by Department of Theater and Performance Studies, University of Dhaka

"Full Moon Meditation" organized by Department of Theater and Performance Studies, University of Dhaka

22h | TBS Graduates
10 cricketers who have played over 400 T20 matches

10 cricketers who have played over 400 T20 matches

22h | TBS SPORTS

Most Read

1
Photo: Courtesy
Panorama

From 'Made in Bangladesh' to 'Designed in Bangladesh'

2
Master plan for futuristic Chattogram city in the making
Districts

Master plan for futuristic Chattogram city in the making

3
Photo: Collected
Crime

Prime Distribution MD Mamun arrested in fraud case

4
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

5
Photo: Collected
Startups

ShopUp secures $30m debt financing to boost expansion, supply chain

6
ICB to withdraw Padma Bank investment as return eludes
Banking

ICB to withdraw Padma Bank investment as return eludes

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net